899 related articles for article (PubMed ID: 8890894)
1. Quantitation of the density of cell surface carbohydrate antigens on cancer cells with a sensitive cell-suspension ELISA.
Ravindranath MH; Bauer PM; Cornillez-Ty C; Garcia J; Morton DL
J Immunol Methods; 1996 Oct; 197(1-2):51-67. PubMed ID: 8890894
[TBL] [Abstract][Full Text] [Related]
2. Cell surface reactive human monoclonal antibody directed to human melanoma-associated gangliosides.
Abdel-Wahab Z; Li WP; Darrow T; Nudelman ED; Towell A; Seigler HF
Melanoma Res; 1993 Dec; 3(6):415-23. PubMed ID: 8161881
[TBL] [Abstract][Full Text] [Related]
3. Cellular cancer vaccine induces delayed-type hypersensitivity reaction and augments antibody response to tumor-associated carbohydrate antigens (sialyl Le(a), sialyl Le(x), GD3 and GM2) better than soluble lysate cancer vaccine.
Ravindranath MH; Bauer PM; Amiri AA; Miri SM; Kelley MC; Jones RC; Morton DL
Anticancer Drugs; 1997 Mar; 8(3):217-24. PubMed ID: 9095325
[TBL] [Abstract][Full Text] [Related]
4. Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins.
Cheresh DA; Pierschbacher MD; Herzig MA; Mujoo K
J Cell Biol; 1986 Mar; 102(3):688-96. PubMed ID: 3005335
[TBL] [Abstract][Full Text] [Related]
5. An epitope common to gangliosides O-acetyl-GD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy.
Ravindranath MH; Morton DL; Irie RF
Cancer Res; 1989 Jul; 49(14):3891-7. PubMed ID: 2472199
[TBL] [Abstract][Full Text] [Related]
6. Endothelial-selectin ligands sialyl Lewis(x) and sialyl Lewis(a) are differentiation antigens immunogenic in human melanoma.
Ravindranath MH; Amiri AA; Bauer PM; Kelley MC; Essner R; Morton DL
Cancer; 1997 May; 79(9):1686-97. PubMed ID: 9128983
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibody-defined correlations in melanoma between levels of GD2 and GD3 antigens and antibody-mediated cytotoxicity.
Thurin J; Thurin M; Kimoto Y; Herlyn M; Lubeck MD; Elder DE; Smereczynska M; Karlsson KA; Clark WM; Steplewski Z
Cancer Res; 1987 Mar; 47(5):1229-33. PubMed ID: 3815333
[TBL] [Abstract][Full Text] [Related]
8. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues.
Real FX; Houghton AN; Albino AP; Cordon-Cardo C; Melamed MR; Oettgen HF; Old LJ
Cancer Res; 1985 Sep; 45(9):4401-11. PubMed ID: 4028024
[TBL] [Abstract][Full Text] [Related]
9. Ganglioside antigens in tissue sections of skin, naevi, and melanoma--implications for treatment of melanoma.
Hersey P
Cancer Treat Res; 1991; 54():137-51. PubMed ID: 1673856
[TBL] [Abstract][Full Text] [Related]
10. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines.
Hakomori S
Adv Exp Med Biol; 2001; 491():369-402. PubMed ID: 14533809
[TBL] [Abstract][Full Text] [Related]
11. Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells.
Welt S; Carswell EA; Vogel CW; Oettgen HF; Old LJ
Clin Immunol Immunopathol; 1987 Nov; 45(2):214-29. PubMed ID: 3665201
[TBL] [Abstract][Full Text] [Related]
12. Immunorecognition of ganglioside epitopes: correlation between affinity and cytotoxicity of ganglioside antibodies.
Dippold W; Bernhard H
Eur J Cancer; 1992; 28A(10):1605-10. PubMed ID: 1382491
[TBL] [Abstract][Full Text] [Related]
13. Ganglioside GD2 in reception and transduction of cell death signal in tumor cells.
Doronin II; Vishnyakova PA; Kholodenko IV; Ponomarev ED; Ryazantsev DY; Molotkovskaya IM; Kholodenko RV
BMC Cancer; 2014 Apr; 14():295. PubMed ID: 24773917
[TBL] [Abstract][Full Text] [Related]
14. The addition of exogenous gangliosides to cultured human cells results in the cell type-specific expression of novel surface antigens by a biosynthetic process.
Furukawa K; Thampoe IJ; Yamaguchi H; Lloyd KO
J Immunol; 1989 Feb; 142(3):848-54. PubMed ID: 2464027
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of melanoma-associated gangliosides in cancer patients.
Tai T; Cahan LD; Tsuchida T; Saxton RE; Irie RF; Morton DL
Int J Cancer; 1985 May; 35(5):607-12. PubMed ID: 3997282
[TBL] [Abstract][Full Text] [Related]
16. Cell surface accessibility of individual gangliosides in malignant melanoma cells to antibodies is influenced by the total ganglioside composition of the cells.
Lloyd KO; Gordon CM; Thampoe IJ; DiBenedetto C
Cancer Res; 1992 Sep; 52(18):4948-53. PubMed ID: 1516051
[TBL] [Abstract][Full Text] [Related]
17. Fluctuations in the expression of a glycolipid antigen associated with differentiation of melanoma cells monitored by a monoclonal antibody, Leo Mel 3.
Werkmeister JA; Triglia T; Mackay IR; Dowling JP; Varigos GA; Morstyn G; Burns GF
Cancer Res; 1987 Jan; 47(1):225-30. PubMed ID: 3791209
[TBL] [Abstract][Full Text] [Related]
18. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21.
Ragupathi G; Meyers M; Adluri S; Howard L; Musselli C; Livingston PO
Int J Cancer; 2000 Mar; 85(5):659-66. PubMed ID: 10699946
[TBL] [Abstract][Full Text] [Related]
19. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.
Ragupathi G; Livingston PO; Hood C; Gathuru J; Krown SE; Chapman PB; Wolchok JD; Williams LJ; Oldfield RC; Hwu WJ
Clin Cancer Res; 2003 Nov; 9(14):5214-20. PubMed ID: 14614001
[TBL] [Abstract][Full Text] [Related]
20. Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model.
Ruf P; Schäfer B; Eissler N; Mocikat R; Hess J; Plöscher M; Wosch S; Suckstorff I; Zehetmeier C; Lindhofer H
J Transl Med; 2012 Nov; 10():219. PubMed ID: 23134699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]